Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
AKBA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.24 - $4.08
Previous CloseN/A
Volume5.66M
Average Volume (3M)3.77M
Market Cap
$726.50M
Enterprise Value$1.06B
Total Cash (Recent Filing)$137.31M
Total Debt (Recent Filing)$53.36M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Nov 06, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding265,145,050
10 Day Avg. Volume3,405,532
30 Day Avg. Volume3,770,499
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.46
Enterprise Value/Revenue5.20
Enterprise Value/Gross Profit6.99
Enterprise Value/Ebitda96.31
Forecast
1Y Price Target
$7.00Price Target Upside155.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Market ExpansionManagement expects total access to Vafseo will exceed 275,000 patients by the end of 4Q25 as additional dialysis organizations come onboard.
Revenue GrowthThe revenue estimate for Auryxia was raised by approximately 80% due to its stability in the first half of the year.
Strategic PartnershipsAkebia's partnership with DaVita represents a significant competitive advantage given DaVita's market leadership in controlling the majority of dialysis care delivery.
Bears Say
Market SaturationVafseo revenues fell below expectations as growth moderated, likely reflecting saturation of the current patient addressable base.
Patent ExpiryAURYXIA lost intellectual property exclusivity in March 2025, with an authorized generic expected to reduce the contribution to total revenues over time as additional potential generic competition is introduced.
Revenue DeclineThe FY25E revenue estimate for Vafseo was reduced by approximately 13% due to weaker than expected performance.
Akebia Therapeutics News
AKBA FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Akebia Therapeutics lowest stock price was $1.24 and its highest was $4.08 in the past 12 months.
What is Akebia Therapeutics’s market cap?
Akebia Therapeutics’s market cap is $726.50M.
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 38 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on Aug 07, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.015 by $0.015.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Akebia Therapeutics have?
Akebia Therapeutics has 265,145,050 shares outstanding.
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of $0 in its last earnings report, beating expectations of -$0.015. Following the earnings report the stock price went down -20.37%.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Currently, no hedge funds are holding shares in AKBA
Akebia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (155.47% Upside)
$7.00 (155.47% Upside)
Blogger Sentiment
Neutral
AKBA Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
106.01%
12-Months-Change
Fundamentals
Return on Equity
91.25%
Trailing 12-Months
Asset Growth
56.95%
Trailing 12-Months
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc. (AKBA) is a biopharmaceutical company that focuses on the development and commercialization of therapeutics for patients with kidney disease. The company operates primarily in the healthcare sector, targeting the nephrology space. Akebia's core products include vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia due to chronic kidney disease (CKD).
AKBA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, with strong revenue growth driven by both Vafseo and Auryxia, significant advancements in clinical trials, and an overall solid financial position. While there were some challenges with adherence rates and potential future competition for Auryxia, the positive aspects and future prospects significantly outweighed the negative points.View all AKBA earnings summariesAKBA Stock 12 Month Forecast
Average Price Target
$7.00
▲(155.47% Upside)
Technical Analysis
Oruka Therapeutics
―
Theravance Biopharma
―
Vir Biotechnology
―
ProKidney
―
ArriVent BioPharma, Inc.
―
Ownership Overview
2.26% Insiders
8.61% Mutual Funds
6.02% Other Institutional Investors
71.23% Public Companies and
Individual Investors